022CBIC's 4th Cell Bioindustry Conference and the 2nd China Biomedical Innovation Cooperation Conference will grandly hold in Beijing from July 28 to 29, 2022. The conference will invite authoritative experts of biomedical and industry-leading experts to share the most cutting-edge information and policy trends in the fields of immune cell therapy, stem cells, organoids, exosomes, single cells, antibodies and new drugs, gene therapy, oncolytic viruses, etc., and link a multi-party platform for industry, academia, research and investment, and promote industry cooperation and development. sincerely invites you to gather in Beijing in July to participate in the biopharmaceutical industry event!
Conference Agenda (Framework)
CBIC Cell Biological Industry Conference
Topic 1: Cell Therapy Innovation and Application
Topic 2: Stem Cell Clinical Application and Industrial Transformation
Topic 3: 3D Cell culture and organoid clinical application
Topic 4: Multi-combination application of cell exosomes and single-cell sequencing
The second China Biomedical Innovation Cooperation Conference
Topic 1: Research and development and application of new antibody drugs
Topic 2: Gene therapy and oncolytic virus
Topic 3: CXO helps the new development of biomedical
Note: The forum agenda shall be subject to the final announcement of the organizer.
Display range
Biopharmaceutical CDMO enterprises; laboratory instruments/consumables/equipment providers; animal model technology service enterprises; drug analysis/preclinical/CRO service institutions; biotechnology, manufacturing and solutions Case provider; related service providers such as testing/cold chain/informatization/data intelligence/medical translation; raw materials providers such as antibodies/ protein /cells; biological industry parks, etc.
expert lineup
(sorting is indefinitely sequence)
Zhang Yu
Deputy General Manager of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd., Chief Scientific Officer Zhongyuan Pharmaceutical CEO O
) Theme of the speech: To be determined
) Expert introduction:
Beijing University of Aeronautics and Astronautics Bachelor of Biomedical Engineering, Master of Space Life Sciences, Heinrich-Heine-Universität, Germany Düsseldorf) PhD in stem cell and regenerative medicine, dual-recruitment professor at Tianjin Medical University, researcher at the National Stem Cell Product Industrialization Base, and senior engineer. He has served as the president and CEO of Yi'ang Biotechnology (Beijing) Co., Ltd., assistant to the president of Zhongyuan Xiehe , and vice president of R&D of Biotechnology Transfer Center of VCANBIO USA.
During his time in Germany, he served as a lecturer at the University of Science and Technology of Bonn, an assistant researcher at the Helmholtz Center of the German Astronautics Administration, and a visiting scholar at the University of Palermo, Italy. He has presided over or participated in cell technology-related research projects funded by the Ministry of Science and Technology of China, EU, BMBF of the Ministry of Education and Science of Germany, DFG of the German Research Foundation, and has published more than ten high-level SCI papers in the fields of stem cells and regenerative medicine.
Li Dinggang
Beijing Ludaopai Blood Hospital Executive Director
)Speech topic: Explore the multi-fusion of tumor cell immunotherapy and traditional Chinese and Western medicine
) Expert introduction:
Technical director of Oncology Department, member of the International Cryo Surgery Society, member of the Beijing Branch of the Chinese Anti-Cancer Society, member of the General Surgery Society of China. He has studied clinical treatment of tumors in the Department of Oncology Surgery at the Johns Hopkins University School of Medicine.
has been engaged in tumor treatment for more than 30 years. It has been the first in China to carry out comprehensive and personalized tumor treatments, such as chemoradiotherapy, traditional Chinese medicine treatment, as well as argon and helium ultra-cold minimally invasive treatment, thermal therapy, biological treatment and other therapies, and has rich experience in the treatment of middle and late stage tumor patients.
Ying Zhitao
Chief physician of Peking University Cancer Hospital
) Theme of the speech: CSCO CAR Interpretation of the guide to treating lymphoma guide
) Expert introduction:
Youth committee member of the Hematology and Oncology Committee of the Chinese Anti-Cancer Association, member of the Chinese Geriatric Hematology Lymphoma Group, member and secretary of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO), and member of the Professional Committee of the Drug Clinical Research and Evaluation of the Chinese Association of Geriatric Health Care.
has been using CAR T cells to treat relapsed and refractory B-cell lymphoma in China since 2013. One of the results of the study was accepted and published by Nature Medicine. In addition, as the main participant, the registered clinical study (RELIANCE study) of CAR T products (relma-cel) targeting CD19, the related products have been approved for marketing in China. Written by CSCO's first edition of "Guidelines for the Management of Infections Related to CAR-T Cells in the Treatment of Hematologic Malignant and Immune Targeted Therapy".
Qi Yanchao
333Chief physician
)Telephone topic: Healthy human Immune cell Tremium treatment for advanced tumors: clinical application research, opportunities and challenges
) Expert introduction:
National second-level professor, chief physician, national outstanding contribution expert.
has served as director of the Biotherapy Center of the Cancer Hospital Affiliated to Guangzhou Medical University.
is currently the chief physician of the Third Affiliated Hospital of Guangzhou Pharmaceutical University and the chief expert of Guangzhou Kunsheng Biotechnology Co., Ltd.
also serves as executive director of the World Health Association Federation, director of the World Neurological Rehabilitation Association, executive member of the Oncology Professional Committee of the Chinese Society of Geriatrics, member of the Stem Cell Professional Committee of the Chinese Medical Association, expert of the National Natural Science Foundation of China, member of the Guangdong Provincial Medical College Senior Professional Title Review Committee; Deputy Editor-in-Chief of " Chinese Journal of Practical Neurological Diseases ", etc.
has been engaged in clinical application research and tumor biotherapy for more than 30 years, and has specialized in basic theoretical clinical application research on cell immunotherapy for middle and late stage tumors. Since 1985, it has undertaken and completed more than 30 National Natural Science Foundations for key research projects in the Ministry of Science and Technology. He won 12 scientific research achievements and 19 achievement awards. Three national invention patents. Published 3 monographs. More than 200 papers have been published.
Bi Xinwen
Chief Scientific Officer of Sinochem Medical Investment Holdings (Shenzhen) Group Co., Ltd., Chief Scientific Officer of Shenzhen Stem Cell Bank, and Director of the Oncology Rehabilitation Department of Tai Ingredient Hospital
)Telection Topic: Photoimmunotherapy in the field of tumor treatment Innovative application
) Expert introduction:
imperial doctor Bi Zhong descendant, grandfather Bi Cikai, grandfather Bi Qiming and above 9 generations are all famous local doctors, and each generation of family has medical books passed down. At the age of five, he started to learn traditional ancient Chinese medicine with his grandfather, studied , Guangzhou Medical University clinical medicine, graduate student studied biomolecular science at Sun Yat-sen University, and was a researcher in the tumor laboratory of Baylor Medical College in the United States. Tianjin Science and Technology Press published "Tumor Microenvironment and Immune Tolerance" SBN:978-7-5576-8027-5 Chinese Version Library CIP Data Nuclear (2020) No. 104514, and compiled the content of chapters 2, 4, 6 and 7 (total: 170,000 words); it has also made outstanding contributions to the diagnosis and treatment of immune-related renal diseases, and published "Progress in Diagnosis and Treatment of Immune-related Related Renal Diseases" ISBN 978-5576-7490-8 The book No. 050479 of the Chinese Version Library (2020) serves as the deputy main article, and has compiled Chapters 6, 7, 9, and 10 (total: 74,000 words), and has published 6 papers at home and abroad. 2002 was rated as number: 20220052 "Hundred Special Medical Contributors" by the Chinese Famous Doctors Network. It inherits the culture of traditional Chinese medicine, upholds the spirit of "the sincerity of great doctors", and returns to life with great hands.
has profound attainments in China's regenerative medicine and precision medicine. It has made outstanding contributions to the research and development of regenerative medicine in China, such as organ repair, kidney cells, liver cells, ovaries, and skin repair. It has also developed precision medicine sub-health equipment to solve the four high-level one-stop solutions, and implemented them in major health care bases. He serves as the head of the expert group of the China Health and Culture Association Non-drug Therapy Practice Center.
Bi Xinwen integrates Chinese and Western medicine, has the thinking of traditional Chinese medicine, and has the theoretical foundation of Western precision medicine and life sciences. He serves as the director of the International Institute of Dietary Nutrition, President of the Chinese Medicine Group, Shenzhen Stem Cell Science and Technology Museum, and the key departments for establishing immune-related diseases in Guangzhou hospitals, especially in the field of regenerative medicine and difficult and complicated immune diseases, which have made unique achievements and effects. ml4 has a unique solution in the treatment of tumors. It is good at various difficult diseases myasthenia gravis , ankylosing spondylitis, lupus erythematosus , rheumatoid arthritis, systemic immune diseases and the regulation of late tumor microenvironment, reversal of late complications of diabetes, awakening of vegetatives, regeneration of renal failure, and many successful cases and good results. Patients at home and abroad have come here.
Yubaofa
Shandong Baofa Tumor Treatment Co., Ltd.Chairman
)Telephone topic: Ultraminal tumor autoimmune therapy
)Expert introduction:
Yubaofa Baofa Yu, M.D. Chief Physician of China, Add-time Professor of (El Paso) of Texas University (2016) Adjunct Professor, Western University of Health Sciences (2016).
988 Chinese Union Medical University ( Peking Union Medical College ), graduated from graduate school, 1990-1992 American UCSD , and postdoctoral fellow Salk from 1992-1994.
994-1998 Assistant Adjunct Professor, UCSD. During his time in the United States, he mainly engaged in the research on cancer drug carrier delivery and tumor molecular biology research.
He invented a new concept and treatment method for using tumor tissue as a sustained-release system for anti-cancer drugs, which has clinical application value.
returned to China in 1998 to establish Taimeibaofa Cancer Hospital in Dongping with technical investment, Jinan Baofa Cancer Hospital (2004), Dongping Baofa General Hospital (2010), Beijing Baofa Cancer Hospital (2012), and ISO Drug Company in the United States (2016).
Zuo Yujie
Beijing Deheng (Chongqing) Law Firm Partner, lawyer
) Speech topic: IPSC and derivative cell preparation and industrialization Application core legal issues research
) Expert introduction:
Beijing Deheng (Chongqing) Law Firm Partner, lawyer. He has successively performed his duties in China Merchants Securities and CITIC Securities . He has more than ten years of securities investment banking and legal practice background. He holds the qualifications of mainland quasi- sponsor representative , Hong Kong 16 sponsors, securities investment consultants, etc., and his business areas are IPO, mergers and acquisitions, restructuring and investment and financing. Lawyer Zuo has long been committed to the research on legal practices and regulatory mechanisms in the fields of cutting-edge life technology, biomedicine, etc., aiming to explore more compliance-enhanced transaction structures and paths for the industry, and published a series of research articles in the fields of organoids, cell and gene therapy, stem cell applications, etc.
Chen Chao
Wenzhou Weike Bio Experimental Equipment Co., Ltd. General Manager
) Theme of the speech: isolator system and A-level environment cell culture system role in cell sterile production process
) Expert introduction:
is currently the technical general manager of Wenzhou Weike Bio Experimental Equipment Co., Ltd. is "JB/T 20175-2017 Sterile Isolator", "JB/T 20180-2017 Glove Leak Tester for Isolation Devices", "JB/T 20177-2017 Hydrogen Peroxide Generator", etc., has been engaged in research on environmental microbial control in Wenzhou Weike Bio for 39 years. He is the general head of the technology research and development team of Weike Bio. has rich experience in development, verification and solution implementation in the fields of hydrogen peroxide sterilizer, sterile isolators, microbial inspection and other fields.
Chen Furong
Tianjin Tiancheng New Drug Evaluation Co., Ltd. Technical Director of Pharmacy Technological
) Theme of the speech: Stem Cell Drug-Non-clinical Pharmacy Evaluation Strategy and Case Sharing
) Expert introduction:
Tianjin Tiancheng New Drug Evaluation Company Pharmacy Technological Director. He has been engaged in non-clinical pharmacodynamic evaluation of new drugs for 14 years. As the head of the topic, he has completed dozens of non-clinical pharmacodynamic evaluation of new drugs, obtained 12 clinical approval documents, 3 patents, participated in the national major science and technology projects and 7 Tianjin science and technology projects, and published 24 articles. The main research directions are endocrine metabolism, antithrombotic fields, and pharmacodynamic evaluation of ophthalmic drugs. As the project leader, we have completed non-clinical pharmacodynamics and PK/PD research on target new drugs such as SGLTh, GCGR/GLP-1R, P2Y2, and FⅪa.
weeks before light
Director of the Anti-Aging and Regenerative Medicine Center of Shenzhen University
) Theme of the speech: Advanced medical application in longevity medicine
) Expert introduction:
Professor of medical cell biology at Shenzhen University, doctoral supervisor, expert in stem cell anti-aging and regenerative medicine, founder/manager of national high-tech, advanced medicine (Advanced Therapeutics and Medicinal Products are a promoter of successful transformation and industry, believers and promoters of "intellectual longevity". Zheng Lemin Deputy Director of the Institute of Cardiovascular Research, Peking University ) Topic of the speech:
) Expert introduction:
, Deputy Director of the Institute of Cardiovascular Research, Peking University, and Assistant Director of the Key Laboratory of the Ministry of Education. Director, researcher, doctoral supervisor of the Cardiovascular Metabolism and Proteomics Research Office, majoring in Pathophysiology . Obtained the "Excellent Youth Fund" of the National Natural Science Foundation of China; the "Ten Thousand Talents Program" Youth Top Talents Fund of the Ministry of Education; the "New Century Talent Fund" of the Ministry of Education. He also presided over the National Natural Blood Vessel Major Special Cultivation Fund, including 7 National Natural Natural Science Foundations, Beijing Market Fund (2 projects), and other funds. He participated in the Ministry of Science and Technology’s major special projects and 973 projects (4 projects). He won two Chinese Medical Awards and provincial and ministerial awards, American Heart Association "Pre-doctoral Fellowship Award", etc. A total of 116 SCI articles have been published, including 83 SCI responsible authors, and SCI cited more than 4,400 times. Articles of the main author ( corresponding author includes co- and first authors) include European Heart Journal (IF=35.855); Advanced Material (IF=32.086); Gastroenterology (IF=33.883); Nature Communications (IF=17.694); Advanced Science (IF=17.521); Advanced Functional Materials (IF=19.924) (2 articles), etc. In 2010, the invention patent was passed by the US Patent Office and the European Patent Office, and a total of 4 Chinese patents were obtained from 2019-2022 (first inventor).In 2014, it obtained one of the National CFDA Cardiovascular Clinical Medical Test Kits, and in 2020, it obtained nine batch numbers of the clinical medical test kits. The professional English book "HDL and Metabolism" was published by Springer Nature Publishing House in May 2022.
Research direction:
. lipoprotein , lipid metabolism, and cardiovascular and cerebrovascular function research. Study the relationship between the three in cardiovascular and cerebrovascular diseases, metabolic diseases, and aging. The focus of lipoprotein research is high-density lipoprotein (HDL), and lipid metabolism includes the related metabolism affected by intestinal flora .
. Vascular functions include cardiovascular, cerebrovascular, etc., especially endothelial cells, and other studies. The proteomics and metabolomics technology are used to study important metabolites in aging-related diseases such as atherosclerosis, as well as the impact of important proteins that regulate metabolism on vascular function.
combined with new materials and new technologies to study the application of cardiovascular and cerebrovascular functions, including the application and research of therapeutic and in vitro diagnostic technologies. Combined with nanoparticle material, mark inflammatory cells, , etc. and transport drugs.
Ding Weiping
Anhui Luohua Biotechnology Co., Ltd. Founder /Chief Scientist
htt ml6
) Theme of speech: Construction and application of organoids and organ chips
) Expert introduction:
successively received two doctoral degrees from University of Science and Technology of China and the University of Washington, USA. He has served as a visiting scholar at the University of Kentucky in the United States and a postdoctoral researcher at the University of Washington in the United States. He returned to China in 2011 to work as an associate professor and doctoral supervisor at the University of Science and Technology of China. has published more than 80 papers in important academic journals and conferences at home and abroad, including more than 40 SCI papers, and more than 30 SCI papers are published as the first author and corresponding author, including , 5 articles in the first and 8 articles in the second category of , and 8 articles in the second area; 1 papers in the first area were published in BIOMATERIALS, J MEMBRANE SCI; 2 papers were published in ANN BIOMED ENG, MOL PHARMACEUT, INT J HEAT MASS TRAN, AICHE J, etc. He has won the " Dean's Excellent Award of Chinese Academy of Sciences" and the "Youth Teacher Career Award (USTCAF)". He has participated in the writing of 1 monograph and applied for 6 patents.
serves as a member of the Medical Imaging and Equipment Subcommittee of the Chinese Society of Diagrams, and is a member of the IEEE, ASME member, Chinese Society of Biomedical Engineering senior member, International Society of Low Temperature Biomedical, and a backbone member of the Anhui Provincial Center for Life Resources Preservation and Artificial Organ Engineering. He has served as "J MEMBRANE SCI", "CHEM ENG SCI", "APPL THERM ENG", "BIOMED MICRODEVICES", "OSTEOARTHR CARTILAGE", "SEP PURIF REV", "INT Reviewer of more than ten important international academic journals, including JPHARMACEUT and MOL PHARMACEUT.
presided over 1 National Natural Science Foundation of China, 1 Special Research Fund for Doctoral Discipline Points of the Ministry of Education, 1 Anhui Provincial Natural Science Foundation of China, and participated in 1 major research instrument development project of the National Natural Science Foundation and 1 major research plan cultivation project. He is currently the head of the Bioengineering Center of the University of Science and Technology of China. He not only has many years of experience in medical instrument research and development, but also many years of experience in theoretical modeling.
Miao Chunguang
General Manager of Anhui Luohua Biotechnology Co., Ltd.
) Speech topic: Organoids and Organ Chips Construction and Application
) Expert introduction:
, male, obtained a master's degree in science from the Hefei Institute of Material Science, Chinese Academy of Sciences in July 2012, and obtained a doctorate in engineering from the University of Science and Technology of China in July 2020. Research directions: biomechanics, cell mechanics, bioadditive manufacturing, bioengineering and smart material , etc.
The core member of the innovation team of the University of Science and Technology of China "The Mechanism of Biomechanics in the Evolution of Specific Diseases" was presided over the participation of the National Natural Science Foundation of China's "Research on the Molecular Mechanism of Mechanical Sensitive Characteristics of Microfilament Skeleton Protein in Mammalian Cells", etc., and has served in the middle and senior management positions of many technology companies.
won the outstanding graduate honor in Graduate School of Chinese Academy of Sciences in 2012, and won the qiushi Award from the Hong Kong Qiushi Science Foundation in 2018, and a national registered engineer. He has published more than ten papers and monographs as the first author and corresponding author, and obtained 19 patent authorizations, and has achieved good economic and social benefits in related patent technologies.
Yin Shenyi
Beijing Jishi Life Technology Co., Ltd.Chief Technology Officer
)Event Lecture Topic: Application and exploration of microtumor PTC in the field of precision medicine
) Expert introduction:
• School of Life Sciences, Peking University, Bachelor of Science
•• Peking University Biomedical Engineering, Ph.D.
• Institute of Molecular Medicine, School of Future Technology, Peking University, Postdoctoral
• School of Medicine, Peking University , Postdoctoral
• Participated in a number of National Natural Science Foundation of China research
• Published 15 high-level SCI articles with the first author and cooperation
• More than 8 years of experience in molecular and cell biology research and development
Zhou Ming
Liwo Biotechnology (Shenzhen) Co., Ltd. Technical Director
) Theme of the speech: China's primary liver cell bank construction and application
) Expert introduction:
Zhou Ming, senior engineer, high-level post-treat talent in Shenzhen, doctoral student of Chinese Academy of Sciences (2010-2015), postdoctoral student of Sun Yat-sen University (2015-2017), technical director of Liwo Biotechnology (Shenzhen) Co., Ltd. (2017-to-present), focuses on the development of underlying technologies such as primary liver cells, organ chips, organoids, artificial organs, etc., and has successively presided over 5 projects such as the National Natural Science Foundation, Postdoctoral Fund, and Shenzhen Science and Technology Innovation Committee. He has published 10 SCI papers as the first author and applied for more than 30 patents.
Ma Yongxian
Aike Jingyi (Beijing) Biomedical Technology Co., Ltd. Chairman and General Manager
) Speech topic: Cancer organoids and primary cell drug screening in clinical application and research -Tumor precision treatment
) Expert introduction:
engaged in cancer research, precision treatment and new drug development for more than 20 years, postdoctoral fellow at the tumor center of Einstein Medical College, New York City, USA, and associate professor at the tumor center of Georgetown University, Washington, USA. He has visited Anderson Cancer Center for a short period of time, Memorial Sloan - Caitlin Cancer Center, Cancer Center affiliated to Harvard Medical School, and the National Cancer Institute. Published: More than 30 articles, including the famous American Science (Science), Nature Sub-journals Oncogene, Cancer Research, etc.
Director of the American Chinese Medical Scientists Association, member of the American Cancer Association, expert of the Capital Haizhi, and CEO of -Aike Jingyi (Beijing) Biomedical Technology Co., Ltd.
Gao Shuai
Doctoral supervisor, China Agricultural University Youth Rising Star Class A Special Young Researcher
) Speech topic: Single-cell level exploration Mysteries of mammalian embryonic development
) Expert introduction:
Doctoral supervisor, China Agricultural University Youth Rising Star A Special Young Researcher A Class A Special Young Researcher.He graduated from China Agricultural University and Beijing Institute of Life Sciences (NIBS) in 2015. He worked as an assistant researcher at the Oriental Hospital Affiliated to Tongji University from 2015 to 2016. He conducted postdoctoral research work at the School of Life Sciences of Peking University from 2016 to 2018. From 2018 to now, he worked at the School of Animal Sciences of China Agricultural University . Mainly engaged in the study of the relevant mechanisms of molecular regulatory networks that determine early embryonic development and stem cell fate in mammals. Currently, as the first or corresponding author, 13 papers have been published in the Nature sub-job Nature Cell Biology and Nature Communications, as well as domestic and foreign journals such as Cell Research and Science Bulletin. The total SCI impact factor is more than 140 points, including 6 articles with more than 10 points. He was invited to write a long review of the application of single-cell technology in the fields of embryonic development and stem cells in the English version of the National Natural Science Foundation of China. He has successively presided over the National Postdoctoral Fund, the National Natural Science Foundation Youth Fund and the General Project, participated in the major research plan of the National Natural Science Foundation, and participated in the key special youth project of the National Key R&D Program "Step Cells and Transformation Research" as the backbone of the project.
Zeng Xun
Zhejiang University professor, doctoral supervisor, National Key Laboratory of Infectious Diseases, First Affiliated Hospital of Zhejiang University, Researcher as a researcher
) Theme of the speech: Application of single-cell mass spectrometry flow in cell therapy
) Expert introduction:
graduated from Stanford University, currently a professor at Zhejiang University and a doctoral supervisor , the National Key Laboratory of Infectious Diseases and the Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, was a researcher at the First Affiliated Hospital of Zhejiang University. He was selected as a researcher at the 2016 Youth National Senior Talent Program of the Organization Department of the Central Committee of the Communist Party of China, and published articles in magazines such as Immunity, eLife, etc.
Li Meng
Shenzhen Huixin Biotechnology Medical Co., Ltd.Product Manager
)Speech topic: High-efficiency purification technology of exosomes and its application in early tumor diagnosis
) Expert introduction:
Currently the product manager of Shenzhen Huixin Biotechnology Medical Co., Ltd. He has worked at Wenzhou Institute of the University of Chinese Academy of Sciences. The main research directions include: 1) Development of an automated exosome separation device based on nano and microfluidic technology; 2) Research on screening of exosome biomarkers in cerebrospinal fluid, , saliva, urine, plasma, and disease biomarker , and biomarker based on automated exosome separation devices; 3) Development of multi-tumor detection technology based on humoral exosomes. Related papers have been published in journals such as Nature Methods, PNAS, ACS Appl. Nano Mater., Anal. Bioanal. Chem.
Han Zhiguo
Agilent Technology Application Engineer
) Speech Topic: Agilent Technology Platform Application Characterization and Quality Control of ADC Drugs
) Expert introduction:
Han Zhiguo, Agilent Technology Application Engineer, the main research direction is the physical and chemical structure characterization of recombinant protein drugs, and has rich experience in liquid phase and mass spectrometry operations. Recently, some non-variable mass spectrometry-related applications have been carried out.
Li Cheng
Researcher at the School of Life Sciences, Center for Statistical Sciences, and Center for Biological Information, Peking University
) Theme of the speech: 3D Genomics and Diseases
) Expert introduction:
995 graduated from the Department of Mathematics of Beijing Normal University in 2001 and graduated from the Department of Statistics of the University of California, Los Angeles in the United States. From 2002 to 2013, he served as an assistant professor and associate professor at the Department of Biostatistics/Dana-Farber Cancer Institute at Harvard University. Since 2013, he has served as a senior researcher at the School of Life Sciences, Center for Statistical Sciences, and Center for Bioinformatics of Peking University.The dChip and ComBat series of genomic data analysis algorithms and software developed by the research group are widely used by peers, and more than 150 academic papers have been published, including papers in Cell, Cancer Cell, Cell Stem Cell, Nature Immunology, and Genome Biology as corresponding authors (including co-) in Cell, Cancer Cell, Cell Stem Cell, Nature Immunology, and Genome Biology. Google Scholar has cumulatively cited more than 35,000 times, and h-index is 66. He is currently a member of the Experimental Hematology Committee of the Chinese Pathophysiology Society and the editor-in-chief of the "Process and Tutorial" column of the "Quantitative Biology" journal. The research group's interests are genomic experimental technology, multi-omic integration analysis, and regenerative biology, and are funded by the National Natural Science Foundation of China's Outstanding Youth Project and the Ministry of Science and Technology's key R&D program.
Li Yixing
Jinsirui China Business Department Application Scientist Team Headministrator
)Team of the speech: Jinsirui CAR-TPreclinical research l4 one-stop solution (tentative)
) Expert introduction:
Doctor Li Yixing Bachelor of biology In 2002, Bachelor of biology from Nankai University in 2008, and obtained a PhD in biomedical degree from Auburn University in the United States. He has successively engaged in research at Michigan State University, Stanford University, etc., and mainly focuses on glucose and iron metabolism in various cell and animal models. Dr. Li has rich scientific research experience in microbiology, molecular cell biology and biochemistry, as well as scientific research results such as 19 documents and 2 patents.
In 2016, Dr. Li Yixing joined Kingsrui American Company. He has served as technical support manager , regional technical support manager , molecular biology and primer application scientists, , is currently the head of the application scientist team of China Business Department .
Xiao Shaowen
Chief physician of the Department of Radiotherapy at Peking University Cancer Hospital
)Telephone topic: Gene therapy combined with thermal radiation therapy to treat advanced malignant tumors
) Expert introduction:
Xiao Shaowen, male, born in 1969, chief physician of the Department of Radiotherapy at Peking University Cancer Hospital, master's supervisor; member and secretary of the Department of Radiation Oncology at Peking University, and deputy director of the Radiotherapy Teaching and Research Department of Peking University Cancer Hospital. Main academic part-time jobs: Director of the Asian Society of Thermotherapy; Executive Director of the China-Japan Medical Science and Technology Exchange Association and Chairman of the Heat Therapy Professional Committee; Director of the Chinese Society of Clinical Oncology (CSCO), Chairman of the Heat Therapy Professional Committee, and Standing Committee Member of the Nasopharyngeal Carcinoma Professional Committee; Deputy Head of the Thermotherapy Group of the Radiotherapy Branch of the Chinese Medical Association; Standing Committee Member of the Nasopharyngeal Carcinoma Professional Committee of the Chinese Medical Association; Director of the Beijing Cancer Prevention and Treatment Society and Chairman of the Heat Therapy Special Committee, etc.
is mainly engaged in the clinical work of chemoradiotherapy and chemoradiotherapy combined with gene therapy, thermal therapy and immune targeting of head and neck tumors. It ranks as the leading international position in comprehensive treatments such as tumor radiotherapy and combined with gene therapy and thermal therapy. He has won the Outstanding Paper Award of the 4th Asian Thermotherapy Society and the Second Prize of Beijing Science and Technology Progress (the second person who completed it).
Jiang Yun
Tsinghua Institute of Technology Cell and Gene Therapy Innovation Center Executive Deputy General Manager
) Speech topic: Development opportunities in the nucleic acid industry and production support platform construction in the GMP environment
) Expert introduction:
Executive Deputy General Manager of Beijing Hetang Shenghua Medical Technology Co., Ltd.; Head of the Cell and Gene Therapy Innovation Center of Tsinghua Institute of Technology;
CTU-UIBE MBA; Secretary-General of the Synthetic Biotechnology Branch of the China Medical Biotechnology Association; Member of the Workers' and Workers' Party; 2019 Beijing Science and Technology Rising Star
is currently in charge of the operation and construction of the Cell and Gene Therapy Innovation Center of Tsinghua Institute of Technology, presided over 2 scientific and technological projects at the provincial level or above, and participated in 5 scientific and technological projects at the provincial level or above as a backbone. There are 44 international patents, 5 patents being applied for.He has participated in the research and development of the world's first synthetic biological gene therapy drug SynOV1.1. This product has been licensed through China (CDE) and the United States (FDA) clinical trials, and is also conducting clinical Phase I/IIA clinical research in China and the United States.
Fan Yufei
Director of Oncology Department, Beijing Yanhua Hospital
)Telephone topic: Application of oncolytic virus in the treatment of malignant tumors
) Expert introduction:
Director of Oncology Department, Beijing Yanhua Hospital, Master of Oncology
Member of the China Precision Medicine and Tumor Rehabilitation Committee
Young member of the Asia-Pacific Gene and Cell Treatment Committee
Member of the Breast Disease Committee of Beijing Medical Association
Member of the Beijing Cancer Prevention and Treatment Society Tumor Standardization Promotion and Application Professional Committee Standing Committee
Standing Committee of the Beijing Breast Disease Prevention and Treatment Society Primary Diagnosis and Treatment Committee
Campus Professional Committee of the Fangshan District Medical Association, Beijing
Campus Professional Expert Group for Fangshan District, Beijing
History of the Cancer Center of Churchill Hospital, Oxford University, studied at the Cancer Center, Churchill Hospital, Oxford University, and is good at chemotherapy for middle and late malignant tumors, bioimmunotherapy, gene targeted therapy, minimally invasive intervention and other comprehensive treatments, and is good at the three-stage pain relief treatment of cancer and the diagnosis and treatment of complications of advanced malignant tumors.
Wangyang
R&D Director, Wuhan Binhui Biotechnology Co., Ltd.
)Team: On-Collective Herpes Simplex Virus (OH2)Clinical Research Progress
)Expert introduction: Associate Professor, PhD, Master's Supervisor. Hubei Province "Chutian Scholars Program" Chutian student, Wuhan City's "3551 Optics Valley Talent Program" selected. R&D Director of Wuhan Binhui Biotechnology Co., Ltd. Mainly engaged in: oncolytic virus (OH2) anti-tumor mechanism research; preclinical and clinical trials of new Class I anti-tumor drug OH2; research and clinical research on the anti-tumor molecular mechanism of virus-activated immune cells (VAK).
Gong Shiling
Vitonglihua Chief Product Expert
) Speech Topic: How does animal model help evaluate the preclinical efficacy of cell therapy drugs?
) Expert introduction: As the head of the product of Vitonliva/Charles River RMS, Gong Shiling focuses on in-depth research on humanized animal models related to the research and development of tumor immunity (IO) drugs. In 2014, it led the introduction of the first domestic and the first super-severe immunodeficient mouse NOG, which provides a very good animal model platform for the research and development of tumor immune drugs in domestic pharmaceutical companies/CRO/research institutes, and also provides preclinical data support for the launch of many domestic tumor immune drugs.
Note: The above are some experts and topic dynamics, and the actual agenda shall be subject to the final announcement of the organizer.
